Table 1.
Baseline characteristics of patients.
| Training cohort n = 1,658 |
Validation cohort n = 855 |
Standardized difference | p value | |
|---|---|---|---|---|
| Age (years) | 58.5 ± 10.7 58 [51-65.7] |
58.7 ± 10.3 58 [52-66] |
0.022 | 0.461 |
| Male sex (n, %) | 1,103 (66.5) | 587 (68.7) | -0.045 | 0.281 |
| Platelet count (103/mm3) | 154.5 [112–202] | 150 [109–201] | 0.038 | 0.269 |
| AST (IU) | 30 [24-42] | 31 [23–43] | -0.021 | 0.914 |
| AST x N (n = 40) | 0.75 [0.60–1.05] | 0.78 [0.58–1.08] | -0.021 | 0.914 |
| ALT (IU) | 27 [20-39] | 27 [20-40] | -0.002 | 0.771 |
| ALT x N (n = 40) | 0.68 [0.50–0.98] | 0.68 [0.50–1.00] | -0.002 | 0.771 |
| GGT (IU) | 54 [30-118] | 58 [31-123] | -0.054 | 0.246 |
| GGT x N (n = 45) | 1.20 [0.67–2.62] | 1.29 [0.69–2.73] | -0.054 | 0.246 |
| Prothrombin time (%) | 85 [74-95] | 84 [74-95] | -0.020 | 0.936 |
| Albuminemia (g/L) | 42 [38.2-45] | 42 [39-45] | 0.025 | 0.957 |
| Total bilirubin (μmol/L) | 11 [8-17] | 11.9 [8-18] | -0.012 | 0.217 |
| AFP (ng/ml) | 5 [3-10.3] | 5.1 [3-9.5] | 0.037 | 0.728 |
| Cirrhosis aetiology | 0.819 | |||
| Cured HCV | 988 (59.6) | 501 (58.6) | 0.020 | |
| Controlled HBV | 118 (7.1) | 66 (7.7) | -0.023 | |
| Alcohol and/or metabolic | 552 (33.3) | 288 (33.7) | -0.008 | |
| Follow-up (months) | 37.0 [IQR: 23.9–58.3] | 37.2 [IQR: 23.3–55.6] | 0.058 | 0.488 |
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyltransferase.